Quantcast
Last updated on April 16, 2014 at 12:17 EDT

Latest 5-HT3 antagonist Stories

2014-01-29 16:29:05

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/bgdzzw/tesaros) has announced the addition of the "Tesaro's Rolapitant: Competition for Emend" [http://www.researchandmarkets.com/research/bgdzzw/tesaros ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Tesaro's rolapitant is a NK-1 inhibitor in phase III trials for the prophylaxis of chemotherapy-induced nausea and...

2013-12-19 04:20:55

LUGANO, Switzerland, December 19, 2013 /PRNewswire/ -- The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution agreement, covering China, Hong Kong and Macao, for netupitant-palonosetron fixed dose combination (NEPA), a Helsinn product under...

2013-12-09 12:25:55

Seeking indication for prevention of chemotherapy-induced nausea and vomiting LUGANO, Switzerland and WOODCLIFF LAKE, N.J., Dec. 9, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational oral fixed-dose combination capsule of netupitant 300 mg + palonosetron 0.50 mg (NEPA) for prevention of acute and delayed...

2013-10-01 12:29:36

LUGANO, Switzerland, October 1, 2013 /PRNewswire/ -- The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi(R) (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The establishment of this...

2013-08-29 12:26:09

Product Line Momentum is Building FRANKLIN LAKES, N.J., Aug. 29, 2013 /PRNewswire/ -- BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today that the U.S. Food and Drug Administration (FDA) has approved the third drug to be offered in the new BD Simplist(TM) line of ready-to-administer prefilled generic injectables. The third BD Simplist product to launch is Ondansetron Injection, USP 4mg/2mL (2mg/mL),...

2013-05-16 04:23:41

Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...

2012-12-21 08:23:06

POINT RICHMOND, Calif., Dec. 21, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced initial top-line results from its Phase 2 clinical trial evaluating the efficacy and safety of TO-2061 (ondansetron oral tablets 0.5 mg and 0.75 mg) in patients with obsessive compulsive disorder (OCD) who had not adequately responded to treatment with approved first-line therapies. The data from the trial showed that TO-2061 did not meet the primary efficacy endpoint to...

2012-11-28 08:25:03

ALBANY, New York, November 28, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron FDC, APF530 & Rolapitant) Market - Global Market Opportunity Assessment Study, 2012 - 2018 [http://www.transparencymarketresearch.com/cinv-market.html ]," the global CINV market was worth USD 1.3 billion in 2011 and is expected to...

2012-10-24 07:31:41

ALBANY, New York, October 24, 2012 /PRNewswire/ -- According to a new market report published by Transparency Market Research (http://www.transparencymarketresearch.com) "Netupitant - Palonosetron FDC - Global Market Opportunity Assessment Study, 2012 - 2018 [http://www.transparencymarketresearch.com/netupitant-palonosetron-fdc-market.html ]", the global Netupitant - Palonosetron FDC sales are expected to reach USD 515.0 million by 2018. The global Chemotherapy-induced nausea...

2012-10-15 03:23:48

LUGANO, Switzerland and MELBOURNE, Australia, Oct. 15, 2012 /PRNewswire/ -- Melbourne biopharmaceutical company Specialised Therapeutics Australia (STA) has been granted exclusive commercialisation rights to a new drug for the treatment of NSCLC cachexia-anorexia. This condition is a serious multifactorial disorder which involves muscle wasting and metabolic impairment and commonly affects patients with advanced cancer. STA has reached agreement with Swiss pharmaceutical company...